BRIEF-Alpha Cognition Reports Positive Top-Line Results Of Zunveyl® In Alzheimer’s Disease

Alpha Cognition Inc

ACOG

0.00

June 9 (Reuters) - Alpha Cognition Inc ACOG.O:

ALPHA COGNITION REPORTS POSITIVE TOP-LINE RESULTS FROM BEACON REAL-WORLD STUDY OF ZUNVEYL® IN ALZHEIMER’S DISEASE
ALPHA COGNITION - PROVIDERS REPORT FAVORABLE GI TOLERABILITY AND OVERALL EXPERIENCE WITH ZUNVEYL
ALPHA COGNITION - PROVIDERS REPORT IMPROVED SLEEP-RELATED OUTCOMES IN 72% OF ZUNVEYL PATIENTS
ALPHA COGNITION - PROVIDERS REPORT DELAYED OR DISCONTINUED PSYCHOTROPIC MEDICATIONS IN 80% OF ZUNVEYL PATIENTS
ALPHA COGNITION - PROVIDERS REPORT COGNITIVE IMPROVEMENT IN 92% OF PATIENTS AFTER ZUNVEYL INITIATION

Source text: ID:nBw3lPCXVa

Further company coverage: ACOG.O

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.